Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies
View More
Community Practice Connections™: 20th Annual Winter Lung Conference
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Personal Health Information was Released in Change Healthcare Hack
April 23rd 2024UnitedHealth has found 22 screenshots, allegedly from Change Healthcare files, that were posted for about a week on the dark web. Some of these contained personal health information. The extent of data release is not yet known.
Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds
April 22nd 2024It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024
April 16th 2024The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to think about coverage issues.